Upgrading to Outperform: The Trough Is Finally a Number — $25.50 for 2026, a −1.75% Medicaid Bottom, and an Explicit ≥12% Snap-Back in 2027 Off a Washed-Out ~13x Base
Key Takeaways
- The trough is now quantified — that's the upgrade. Management set 2026 adjusted EPS guidance of at least $25.50, anchored Medicaid's operating margin at a −1.75% bottom, and committed explicitly to at least 12% adjusted-EPS growth in 2027 off the 2026 baseline. For three quarters the bear case was "you can't date the bottom"; this print dates it. FY2025 landed at $30.29, exactly on the reset — the negative-revision cycle that defined 2024–25 is over.
- Read the $25.50 against the clean base, not the headline. 2025's $30.29 included $3.75 of nonrecurring items (tax, investment gains, the Q2 settlement), so the clean 2025 run-rate was ~$26.54. The $25.50 guide is therefore roughly flat-to-down ~4% on a clean basis — a far gentler step-down than the −16% headline-to-headline optics suggest, and it absorbs a self-inflicted ~$0.75 of investment drag plus the loss of below-the-line tailwinds.
- The mix is turning the right way underneath. Medicare Advantage margin is guided up more than 100bps to at least 2% (on deliberate ~high-teens membership exits), Stars step up to ~55% of members in 4-star-plus contracts for PY2027, ASO/national accounts had a standout season (won 9 of 11 "second blue bid" opportunities), and Carelon's underlying external growth remains high-teens/low-20s before the affiliated-membership headwind. The repositioning is real, not rhetorical.
- The caveats are honest and priced. The 2027 MA advance notice landed effectively flat — a genuine headwind to the recovery — and management lowered long-term segment margin targets (enterprise to 5–6%) to reflect mix. But the per-line-of-business frameworks are unchanged, and at ~13x a washed-out trough number, a great deal of structural pessimism is already in the price.
- Rating: Upgrading to Outperform from Hold. We set the upgrade trigger at the Q3 call: a credible, achievable, quantified 2026 guide plus a datable Medicaid bottom. This print delivered both, the market reversed an early dip to close +5.9%, and the risk/reward at ~13x a trough EPS with a committed ≥12% 2027 snap-back now favors ownership ahead of the re-rate. The negative-revision regime has flipped to a positive-revision setup.
Results vs. Consensus
Q4 2025 Scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Q4 Operating Revenue | $49.3B | ~$49.0B | Beat | +~0.6% |
| Q4 Adjusted EPS | $3.33 | ~$3.10 | Beat | +$0.23 (tax-driven) |
| FY2025 Adjusted EPS | $30.29 | ~$30 (guide) | In line / slight beat | — |
| Q4 Consolidated BER (MLR) | 93.5% | ~93.0% | In line | +~50bps (flu) |
| FY2025 Consolidated BER | 90.0% | ~90.0% | In line | On guide |
| Year-End Medical Members | 45.2M | ~45.3M | In line | −~500K YoY |
| FY2026 Adj. EPS Guide | ≥$25.50 | ~$27 (Street) | Below Street headline | ~−5% vs Street; ~−4% vs clean 2025 |
Year-Over-Year Comparisons
| Metric | Q4 2025 | Q4 2024 | Change |
|---|---|---|---|
| Operating Revenue | $49.3B | $45.0B | +10% |
| Adjusted EPS | $3.33 | $3.84 | −13.3% |
| Benefit Expense Ratio | 93.5% | 92.4% | +110bps |
| FY Adjusted EPS | $30.29 | $33.04 | −8.3% |
| FY Operating Revenue | ~$198B | $175.2B | +~13% |
| Year-End Membership | 45.2M | ~45.7M | −~1.1% |
The Q4 2024 comp ($3.84) was itself reported alongside the original $34.15–$34.85 FY2025 guide that was subsequently cut twice — so the −13.3% Q4 YoY and −8.3% FY YoY decline measure the cumulative damage of the 2025 cost-trend cycle. The forward story, not the trailing comp, is what changes the rating.
Quarter-Over-Quarter Comparisons
| Metric | Q4 2025 | Q3 2025 | Change |
|---|---|---|---|
| Operating Revenue | $49.3B | $50.1B | −1.6% |
| Adjusted EPS | $3.33 | $6.03 | −44.8% |
| Benefit Expense Ratio | 93.5% | 91.3% | +220bps |
Q4 is structurally the lowest-EPS, highest-MLR quarter for managed care (the benefit ratio peaks as deductibles are exhausted and the ACA "use-it-or-lose-it" surge lands), so the steep QoQ EPS decline is seasonal and expected — management had guided to more H2 earnings in Q3 than Q4. December flu added ~50bps to the Q4 ratio. The signal is that even the seasonally-worst quarter came in on plan.
Quality of Beat/Miss
- Q4 EPS: The $0.23 beat was tax-driven, not operational — greater-than-anticipated tax favorability that lifted the FY nonrecurring tally to $3.75. Underlying operating performance and medical trend came in as expected. Quality-neutral, but management's choice to spend the upside — pulling a quarter of 2026 investment forward plus ~$0.25 of workforce/retention — is a confidence signal about the 2026 base.
- FY2025 result: $30.29 landing on the ~$30 reset is the single most important quality marker of the year — the negative-revision streak ended. The $3.75 nonrecurring disclosure (up from ~$3 at Q3) is candid and recalibrates the clean base to ~$26.54.
- 2026 guide quality: High. The ≥$25.50 is built from a transparent, defensible bridge (Medicaid trough, MA +100bps, stable commercial, Carelon growth, below-the-line normalization) rather than a top-down growth rate — exactly the structure that makes a number believable.
The 2026 Guide & the EPS Bridge
| Metric | FY2025 Actual | FY2026 Guide | Note |
|---|---|---|---|
| Adjusted Diluted EPS | $30.29 (clean ~$26.54) | ≥$25.50 | ~−4% vs clean base |
| Operating Revenue | ~$198B | Down low-single-digit % | Risk membership −low-double-digit %, offset by yields + Carelon |
| Consolidated MLR | 90.0% | 90.2% ± 50bps | Prudent trend + Medicaid acuity |
| Adj. OpEx Ratio | 10.5% | 10.6% ± 50bps | Carelon + AI investment |
| Medicaid Operating Margin | ~−0.5% | ~−1.75% (trough) | Rates lag mid-single-digit trend |
| MA Operating Margin | <2% | ≥2% (+>100bps) | Deliberate exits; high-teens membership decline |
| Buyback | $2.6B | ~$2.3B | Opportunistic; M&A paused |
| 2027 Algorithm | — | ≥12% growth off 2026 base | Explicit recovery commitment |
The bridge to ≥$25.50 (management-disclosed): stable commercial fully-insured plus continued commercial fee-based strength; continued progress toward sustainable ACA performance; Medicaid margin compressing to ~−1.75% (the trough); more than 100bps of MA operating-margin improvement to at least 2%; low-single-digit Carelon operating-gain growth (external momentum partly masked by affiliated-membership declines); and, below the line, a meaningful step-down from the nonrecurrence of 2025's investment income plus a return to a normalized tax rate.
Seasonality (important): management expects ~two-thirds of 2026 adjusted EPS in the first half, with 65% of that in Q1 — i.e., Q1 alone is roughly 43% of the full year. That front-loading is unusually steep and means Q1 2026 is the critical proof point; a clean Q1 effectively de-risks the year, while any Q1 slip would loom large.
Segment Performance & 2026 Setup
| Segment | 2026 Membership | 2026 Margin Direction | Read |
|---|---|---|---|
| Medicaid | ~−750K (same-store) | ~−1.75% (trough) | Rates lag mid-single-digit trend; bottom of the cycle |
| Medicare Advantage | Down high-teens % | ≥2% (+>100bps) | Deliberate exits (PPO + non-core HMO); D-SNP retained |
| ACA / Individual | ≥900K at YE (down) | Improving | Repriced for subsidy expiry + higher acuity |
| Commercial Group (risk) | Down high-single-digit % | Stable | Margin discipline; public-sector pricing exits |
| Commercial ASO / National | Growing | Healthy | Won 9 of 11 "second blue bid" opps; CarelonRx pull-through |
| Carelon (Services + Rx) | — | Low-single-digit gain growth | External +high-teens/low-20s ex-affiliated headwind |
Medicaid — the trough, now a number
Medicaid is guided to a ~−1.75% operating margin in 2026 — explicitly the trough — on mid-single-digit cost trend (roughly twice the historical average) that rates will still lag. Membership is guided down ~750K, all same-store, on continued reverification and program changes. Crucially, Q4's Medicaid margin came in favorable to the October outlook (helped by favorable prior-period development and modest retroactive rates; in line excluding those), and management cited early traction from its targeted care-management actions in high-cost categories (substance-use disorder, behavioral health, specialty pharmacy).
"We continue to view 2026 as a trough year. We expect our Medicaid operating margin to be approximately negative 1.75%, with improvement over time as rates incorporate more current experience and our actions take hold." — Gail Boudreaux, CEO
Assessment: A quantified, prudently-anchored bottom (planned off the Q4 exit, the seasonal low) is exactly what converts ELV from an un-modelable story into a recovery story. The composite mid-single-digit rate increase plus the self-help levers give a credible path off −1.75% toward the 2–4% target. This is the linchpin of the upgrade.
Medicare Advantage — margin up, membership deliberately down
MA membership is guided down a striking high-teens percent in 2026 — but by design. Attrition concentrated in PPO and non-core HMO geographies where ELV chose not to compete on price; D-SNP and core HMO were retained. The payoff is a guided MA operating margin improvement of more than 100bps to at least 2%, with Stars stepping up to ~55% of members in 4-star-plus contracts for PY2027 (from ~40% for PY2026).
"We're positioned to deliver meaningful Medicare margin improvement to at least 2% in 2026. It's a meaningful step up year over year." — Felicia Norwood, President, Government Health Benefits
Assessment: Trading high-teens membership for >100bps of margin is the right call in a flat-rate MA environment, and it is the clearest evidence the franchise is managing for profit over scale. The Stars step-up is a quantifiable 2027 tailwind. The risk is that the membership base shrinks faster than margin can compound — but management is choosing the controllable variable.
Carelon — underlying growth intact beneath the affiliated headwind
Carelon's 2026 reported growth is muted to low-single-digit operating-gain growth because lower affiliated health-plan membership (most pronounced in CarelonRx) masks strong external momentum. Stripping the internal headwind, management pegged underlying growth at high-teens/low-20s in Services and low-double-digit in Rx — consistent with the long-term algorithm. 2025 was Carelon's best growth year ever (Services ~+60%, Rx +20%+).
"If you step back... and you take out that internal membership headwind, our overall growth would have been on the services side, high teens, low twenties. And on the Rx side, in the low double-digit range." — Peter Haytaian, President, Carelon
Assessment: The affiliated-membership drag is real but transitory — it unwinds as the health-plan membership stabilizes in 2027. The external growth engine (oncology, SMI, CareBridge, specialty) is the structural reason the 2027 ≥12% algorithm is credible. Carelon is doing exactly what it was built to do.
Key KPIs
| KPI | FY2025 | FY2024 | Trend | Read |
|---|---|---|---|---|
| Year-end medical members | 45.2M | ~45.7M | ↓ | Medicaid reverification |
| FY benefit expense ratio | 90.0% | ~88.5% | ↑ | On guide — cycle peak nearing |
| FY adj. operating expense ratio | 10.5% | ~10.9% | ↓ | Discipline despite investment |
| Days in claims payable | 41.3 | ~41.5 | → | Stable; low-40s target |
| Operating cash flow | $4.3B (0.8x NI) | higher | ↓ | Dec Medicaid payment timing; ≥$5.5B guided 2026 |
| FY capital returned | $4.1B | — | — | $2.6B buyback + dividends |
Key Topics & Management Commentary
Overall Management Tone: The most confident posture in four quarters. Where Q2 was apologetic and Q3 was carefully provisional, this call was declarative — management led with "2026 is a year of execution and repositioning," put hard numbers on the trough, and repeatedly returned to the ≥12% 2027 commitment as the organizing message. The candor on the $3.75 of nonrecurring items and the proactive decision to spend the Q4 tax upside on 2026 investment read as a team that believes it can see the bottom and wants to be judged on the recovery. The one place management was visibly on the back foot was the just-released flat 2027 MA advance notice, which it addressed with advocacy-mode framing rather than quantified mitigation.
1. The Trough Quantified: $25.50 and the $26.54 Clean Base
The headline is the ≥$25.50 guide, but the analytically critical disclosure is the bridge from 2025: $30.29 reported included $3.75 of nonrecurring help, so the clean 2025 base is ~$26.54, and the 2026 guide is only ~4% below it on an apples-to-apples basis — while absorbing ~$0.75 of pulled-through investment and the loss of below-the-line tailwinds.
"We are establishing 2026 adjusted diluted earnings per share guidance of at least $25.50. As you consider the year-over-year comparison, it's important to remember that our 2025 results included approximately $3.75 per share of favorable nonrecurring items." — Gail Boudreaux, CEO
Assessment: The headline-to-headline −16% optics overstate the operating step-down by a wide margin; the clean-base −4% is the number that matters, and it makes 2026 a controlled trough rather than a collapse. Management framing this proactively is the kind of disclosure that rebuilds the trust the prior two years eroded.
2. The 2027 Algorithm: ≥12% Growth Off the 2026 Baseline
Management committed explicitly to returning to at least 12% adjusted-EPS growth in 2027 off the 2026 ending baseline — and grounded it in levers already in motion rather than a single assumption: pricing actions taken, care-management programs in flight, the MA margin step-up, Stars improvement, and Carelon's external pipeline.
"We have confidence in at least 12% adjusted EPS growth coming off of our '26 ending baseline... the path isn't predicated on a single assumption. It's built on multiple independent levers and disciplined execution across commercial, Medicare, Carelon, and Medicaid." — Gail Boudreaux, CEO
Assessment: ≥12% off ~$25.50 implies ~$28.50+ in 2027 — and at ~13x the trough, the market is paying ~12x a recovering number. The multiple-independent-levers framing is the right defense against single-point-of-failure risk. The credibility hinges on whether the flat MA rate environment lets the MA leg of the bridge hold (see Topic 5).
3. Medicaid: The −1.75% Bottom and the Self-Help Levers
Beyond the rate cycle, management leaned hard on controllable levers: strengthened analytics to flag outlier utilization and billing in high-cost substance-use-disorder settings, expanded behavioral-health and specialty-pharmacy management, and care programs for high-need members. Q4's favorable Medicaid result (ex-PPD/retro) suggests these are beginning to bend trend.
"In Medicaid, we're strengthening our analytics to identify outlier utilization and billing patterns in high-cost substance use disorder treatment settings while maintaining access to clinically appropriate care." — Gail Boudreaux, CEO
Assessment: The shift from "wait for rates" to "rates plus self-help" is what makes −1.75% a floor rather than a way-station. Roughly a third of Medicaid premium reset in January in line with expectations; the rest reprices through the year as 2025 experience flows into state actuarial cycles. The setup is conservative.
4. The Long-Term Margin Recalibration
Management lowered long-term margin targets: enterprise to 5–6%, and Health Benefits, Carelon, and CarelonRx to mid-single-digit (Carelon Services unchanged). Critically, the CFO stressed this is a recalibration of the segment margin to the current business mix — individual ACA is now a larger share of commercial than group, carrying a different profile — not a change to any line-of-business margin framework.
"We have not changed the underlying margin expectation for any line of business within health benefits... this is just a recalibration to better reflect the mix of our business today and a prudent view of the operating environment." — Mark Kaye, CFO
Assessment: This is the one genuinely structural negative in the print, and it deserves weight — a lower segment-margin ceiling caps the long-term earnings-power story even if per-line economics are intact. But "mix recalibration, not strategy change" is a defensible characterization, and at a trough multiple the market is already discounting a haircut. We treat it as a reason to temper the magnitude of the eventual re-rate, not to withhold the upgrade.
5. The 2027 MA Advance Notice: Flat — A Fresh Headwind
The 2027 MA advance notice landed during the call week and was, in management's words, "effectively flat" — failing to keep pace with cost and utilization trend. Boudreaux pushed back forcefully on the policy and flagged the levers carriers are forced to pull when funding lags (benefits, networks, premiums, geography exits).
"At a high level, the advance notice is effectively flat... it just doesn't keep pace with the current medical cost and utilization trends, and that does create real pressure on benefit stability and affordability for seniors." — Gail Boudreaux, CEO
Assessment: The most important caveat to the bull case. A flat 2027 rate notice directly pressures the MA leg of the 2027 recovery bridge — the very segment management is counting on for >100bps of 2026 improvement. The final rate (April) typically firms above the advance notice, and ELV's disciplined, D-SNP-weighted book is better-insulated than a PPO-heavy peer, but this is the variable most capable of derailing the ≥12% 2027 algorithm. It is why this is an Outperform with eyes open, not a table-pound.
6. ACA: Repositioned for the Subsidy Cliff
ELV repriced its individual ACA book for the expiration of enhanced subsidies and higher residual acuity, guiding to at least 900K members at year-end 2026 (down). Encouragingly, membership was up ~10% coming out of open enrollment, aided by modest growth in newer markets — but management cautioned the real swing factor is member premium payment behavior, which only clarifies through the early-April billing cycle.
"On the individual ACA, we are guiding towards at least 900,000 members at year-end 2026... the key swing factor... is really now a situation [of] member premium payments, and that behavior typically is going to become much clearer through early April." — Felicia Norwood, President, Government Health Benefits
Assessment: A smaller, repriced ACA book can carry better margins even as revenue shrinks — the disruption is concentrated in the 2026 transition. The April effectuation read is the near-term ACA checkpoint. Net, ACA shifts from a 2025 drag to a 2026 self-help story.
7. The Investment Pull-Forward and Workforce Spend
Management used the Q4 tax upside to pull one quarter (~$0.25) of the ~$1 of 2026 strategic investment into Q4 2025 and to deploy an additional ~$0.25 toward retention and workforce — leaving ~$0.75 of the investment still embedded in the 2026 guide.
"We pulled forward one quarter of the approximately $1 per share of incremental investments that we had anticipated in 2026... and we deployed an additional 25 cents towards retention and targeted workforce investments." — Mark Kaye, CFO
Assessment: Spending a windfall on forward investment and workforce rather than letting it flatter the headline is a confidence signal — management is optimizing for the 2026/2027 base, not the 2025 optics. It also slightly de-risks the 2026 number by front-loading cost.
8. Capital Allocation: Buyback Steady, M&A Paused
ELV returned $4.1B in 2025 ($2.6B buyback + dividends) and guided to ~$2.3B of repurchases in 2026 within a deliberately conservative near-term posture focused on balance-sheet strength and integration of prior Carelon deals. Management signaled materially lower M&A in 2026 and a greater relative emphasis on opportunistic buybacks at depressed levels.
"At least in 2026, you should expect a lower level of M&A activity and a much greater relative emphasis on opportunistic share repurchases." — Mark Kaye, CFO
Assessment: Buying back ~$2.3B at ~13x trough earnings is accretive and sensible; the M&A pause is the right discipline while integrating. Capital allocation is constructive without being heroic — a steady contributor to the 2027 EPS bridge.
Analyst Q&A Highlights
Whether 2026 cost-trend assumptions are conservative versus the 2025 experience
The opening question pressed on whether the 2026 guide assumes cost trend similar to, better than, or worse than 2025 across each line. Management walked through it line by line, landing on modest moderation off two unprecedented years — Medicaid trend at roughly twice historical norms but easing toward mid-single-digit, ACA accelerating on the subsidy-driven risk-pool shift, commercial stable-but-elevated, Medicare higher on D-SNP mix.
Q: "Are you assuming sort of a similar cost trend in '26 in your embedded guidance to what you experienced in '25? Or is there any place you're assuming it gets worse or better?"
— A.J. Rice, UBS
A: "In Medicaid, we expect cost pressure to remain... at roughly twice the historical average... after two years of fairly unprecedented trend, we do expect some moderation versus 2025. So you could think about cost trend here moving into that mid-single-digit range." — Mark Kaye, CFO
Assessment: The line-by-line transparency is itself reassuring — management is not hiding a single optimistic trend assumption inside an aggregate. Building the guide on "moderation, not recovery" keeps the bar conservative, which is precisely what a trough number should do.
What the larger-than-expected membership declines signal strategically
A recurring line of questioning probed whether 2026 membership declines — bigger than the Street modeled across MA, commercial risk, and Medicaid — reflect competitive weakness or deliberate margin choices. Management was emphatic it is the latter, detailing PPO/non-core exits in MA, public-sector pricing discipline in commercial, and same-store reverification in Medicaid.
Q: "The membership numbers have been lower than we would have thought... across most of the products, is there anything that we should be reading into as far as where you are strategically or competitively... why is this business mix that you're now forecasting different than... a few years ago?"
— Kevin Fischbeck, Bank of America
A: "The headline is no. This is a very disciplined approach in each of the businesses... we made some very conscious pricing decisions around public sector accounts that have been below profitability... this is a repositioning of the portfolio ready for growth." — Gail Boudreaux, CEO
Assessment: The "shrinking for margin, not losing for weakness" distinction is central to the upgrade. The MA margin step-up to ≥2% and the commercial margin discipline corroborate it — this is a managed retreat to profitability, not share loss to competitors. Management answered directly and the numbers back it.
The drivers of the Q4 margin beat and the 2026 segment margin assumptions
An analyst sought the drivers behind the better-than-expected Q4 health-benefits margin and the 2026 assumptions for ACA and MA margins. The CFO disclosed that Q4 Medicaid tracked slightly better on favorable prior-period development and modest retroactive rates (in line excluding those), and previewed the 2026 framework — Medicaid pressure offset by MA improvement and better ACA.
Q: "You mentioned Medicaid margins of minus 1.75%... you did say that margins were a little better than expected in the fourth quarter. Can you expand on the drivers... And any color on where guidance assumptions sit for margins for the exchanges and Medicare Advantage?"
— Justin Lake, Wolfe Research
A: "On Medicaid, margins were pressured in the fourth quarter, but they did track slightly better than our outlook... if you exclude those two items, Medicaid margins completely in line... we are expecting a first-quarter headwind of about 20 basis points for flu that's already embedded in our outlook." — Mark Kaye, CFO
Assessment: The clean-vs-reported Medicaid bridge and the proactive disclosure of the embedded 20bps Q1 flu headwind are exactly the granular, no-surprises framing the Street needed. Pre-embedding the flu headwind reduces the risk of a Q1 negative surprise in the seasonally-critical quarter.
Confidence in the ≥12% 2027 growth algorithm
A direct challenge asked what specifically gives management confidence in ≥12% growth from 2027 after two years of misses, and whether it embeds the 2027 MA rate notice. Management grounded the answer in the 2025 foundation-laying (pricing discipline, execution, Carelon) and the multiple-independent-levers structure, declining to lean on any single driver.
Q: "What gives you that confidence to confirm the long-term EPS growth target of 12% plus starting in 2027 in light of the trends that you've seen in the past two years? ... I assume this includes your view of the 2027 MA rates post the prelim notice?"
— Josh Raskin, Nephron Research
A: "Over the past two years, we've made very specific portfolio targeted decisions, our pricing has hardened, and our operating decisions are designed to protect our earnings base... the path isn't predicated on a single assumption. It's built on multiple independent levers and disciplined execution across commercial, Medicare, Carillon, and Medicaid." — Gail Boudreaux, CEO
Assessment: Management did not fully dispel the MA-rate overhang on 2027 — the answer was framework-level rather than quantified against the flat notice. The multiple-levers argument is sound, but the honest read is that the 2027 ≥12% has a known headwind it must overcome, which is why we size the eventual re-rate conservatively.
What the "2026 ending baseline" means for the 12% math
The final question pressed for precision on the ≥12% base: given the heavy H1 front-loading, is the 2027 growth measured off a Q4-run-rate or the full-year 2026 number, and how are one-time items treated. The CFO used it to recap the full ≥$25.50 bridge and clarified the building blocks.
Q: "Can you just contextualize a little bit more what does the ending baseline mean? ... Should we kind of be thinking about that last period run rate as the baseline for 12% growth?"
— George Hill, Deutsche Bank
A: "You could think about the EPS bridge to $25.50 as... stable performance in commercial fully insured... Medicaid margins compressing to approximately negative 1.75... more than a 100 basis points of operating margin improvement in Medicare Advantage to at least 2%... and below the line, a meaningful step down reflecting the nonrecurrence of the 2025 investment income and a return to a more normalized tax rate." — Mark Kaye, CFO
Assessment: The CFO recapping the entire bridge as the closing answer was a deliberate emphasis on transparency — the number is decomposed, not asserted. The base is the full-year 2026 figure (≥$25.50), so ≥12% implies ~$28.50+ in 2027, the anchor for the valuation case.
Reconciling the larger Medicaid membership decline with the −1.75% margin guide
An analyst probed whether the ~750K Medicaid membership decline reflects a state exit (e.g., Georgia) or pure same-store attrition, and how a bigger membership drop squares with the unchanged −1.75% margin. Management confirmed same-store reverification and walked through the three margin assumptions (elevated trend, lagging rates, self-help levers).
Q: "The Medicaid membership expected decline... Is that all same store, or does that contemplate an exit of a state or an end of a contract?... wanted to try to reconcile that that additional membership decline doesn't further disrupt the margin?"
— David Windley, Jefferies
A: "We've guided to Medicaid membership decline around 750,000 members for 2026. And this really reflects same store... [margin] is really grounded in three core assumptions... cost trend is going to remain elevated... rates... will still lag trend... and not relying on rates alone." — Felicia Norwood, President / Mark Kaye, CFO
Assessment: Confirming same-store (no disruptive state exit baked in) supports the conservatism of the −1.75% and leaves a possible exit as upside optionality rather than a planning crutch. The reconciliation was clean.
What They're NOT Saying
- A point estimate. The guide is "at least $25.50," not a range with a midpoint — management is preserving room to beat, a deliberate inversion of the prior two years' over-promise pattern. The "at least" framing is a feature, but it leaves the realistic high end unstated.
- The clean-basis growth rate in plain terms. Management emphasized the $3.75 of nonrecurring items but never said "2026 is only down ~4% on a clean base" — leaving the more flattering apples-to-apples comparison for analysts to compute.
- The dollar impact of the flat 2027 MA notice on the ≥12% algorithm. Management advocated against the notice but did not quantify what a flat-vs-trend rate does to the MA leg of the 2027 bridge — the single biggest unspoken risk to the recovery commitment.
- Whether the lower long-term segment-margin targets imply a lower long-term EPS dollar trajectory. The "mix recalibration, frameworks unchanged" framing sidesteps whether through-cycle earnings power is structurally lower.
- ACA effectuation risk. The ≥900K guide hinges on member premium-payment behavior that management admits won't clarify until April — a deferred unknown sitting inside a heavily front-loaded year.
Market Reaction
- Pre-print setup: ELV closed at $322.92 on January 27, having drifted down 7.9% in the first weeks of 2026 and 7.3% over the trailing 30 days, and down 20.3% over the trailing twelve months — entering the print de-rated and with low expectations, well within a $275–$453 52-week range.
- Reaction-day move: The stock initially dipped (~−2.3% to an intraday low of $315.46) on the below-Street ≥$25.50 headline, then reversed hard to close at $341.85, up 5.9% (+$18.93), near the top of a wide $315.46–$347.47 (+7.6%) intraday range, on ~3.1x normal volume (4.4M vs. a 1.4M 30-day average). The S&P 500 closed flat — the entire move was idiosyncratic.
- Where it sits: The $341.85 close put ELV at roughly 13.4x the ≥$25.50 trough guide and ~12x a ≥12%-growth 2027 (~$28.50) — a valuation that prices a permanently-impaired health plan, not a franchise with a committed snap-back.
The intraday reversal is the tell. A knee-jerk dip on a below-consensus headline that flips to a near-7% green close is the market re-reading the print: not "guidance is light," but "the trough is finally a number, the negative-revision cycle is over, and there is a committed ≥12% recovery on the other side." After eighteen months of selling every Elevance print, the buyside used a low-expectations setup and a quantified bottom to start discounting the recovery. That shift in reaction function — from "sell the cut" to "buy the trough" — is itself a leading indicator that the de-rating has run its course.
Street Perspective
Debate: Is $25.50 a true trough or another waystation to a lower number?
Bull view: The number is built bottom-up from a transparent bridge, planned off the Q4 seasonal low, with a 20bps flu headwind already embedded and self-help levers showing early Q4 traction — this is a conservative floor management intends to beat ("at least").
Bear view: The same team guided $34+ for 2025 and cut it twice; with a flat MA rate notice and ACA effectuation unresolved until April, ≥$25.50 could still prove optimistic in a year that's 43% back-loaded into Q1.
Our take: The structural difference from 2025 is that FY2025 actually landed on its reset and the 2026 number is decomposed rather than top-down. We credit ≥$25.50 as a genuine trough with beat potential — the burden of proof has shifted, and Q1's outsized weighting means we'll know early.
Debate: Does the flat 2027 MA notice + lowered long-term margins break the ≥12% recovery?
Bull view: The final MA rate firms above the advance notice every year, ELV's D-SNP-weighted book is insulated, and the ≥12% rests on multiple independent levers (Medicaid rate catch-up, Carelon, commercial, Stars) — no single rate notice can break it.
Bear view: A flat notice directly undercuts the MA margin leg management is leaning on, and the just-lowered segment-margin targets signal the through-cycle earnings ceiling is structurally lower — the ≥12% may slip or arrive off a smaller base.
Our take: This is the real risk and we don't dismiss it — it's why our target embeds a sub-historical multiple. But a diversified ≥12% bridge with several non-MA legs, off a washed-out base, survives a flat MA notice even if it doesn't sail through it. We size the re-rate conservatively rather than withhold the upgrade.
Debate: Valuation — does ~13x the trough plus a committed recovery make this an Outperform?
Bull view: ~13x a conservative trough EPS, with the negative-revision cycle over, a ≥12% 2027 snap-back committed, a fast-growing Carelon, and a Stars tailwind — the patient buyer is being paid to own the bottom before the multiple normalizes toward the mid-teens.
Bear view: Buying a down year at a full-ish multiple-on-trough, with structurally lower long-term margins and a live MA-rate headwind, risks paying for a recovery that arrives slower and smaller than the algorithm promises.
Our take: The asymmetry has flipped. With the bottom dated and sentiment washed out, the downside is better-protected (a guide-down is now the tail, not the base case) and the upside — a re-rate as 2026 quarters confirm the trough and 2027 visibility builds — is the more likely path over 12 months. That is an Outperform.
Model Update Needed
| Item | Prior Assumption | Updated | Reason |
|---|---|---|---|
| FY2025 Adjusted EPS | ~$30 | $30.29 (clean ~$26.54) | Actual; $3.75 nonrecurring |
| FY2026 Adjusted EPS | ~high-$20s (flat-to-down) | ≥$25.50 | Quantified trough guide |
| FY2026 Medicaid margin | Down ≥125bps | ~−1.75% (trough) | Confirmed bottom |
| FY2026 MA margin | Improving | ≥2% (+>100bps) | Exits + Stars |
| FY2027 Adjusted EPS | Recovery (unquantified) | ~$28.50+ (≥12% off 2026) | Explicit algorithm; haircut for flat MA notice |
| Long-term enterprise margin | Higher | 5–6% | Mix recalibration |
| 2026 buyback | — | ~$2.3B | Accretive at trough multiple |
Valuation framework: We move to a fair-value range of roughly $385–$415, equivalent to ~14–15x a ~$28 normalized/2027 earnings power (≥12% off the ≥$25.50 trough) — a multiple that remains below ELV's historical mid-teens-to-high-teens range to haircut for the flat MA notice and the lowered long-term segment margins. Against the $341.85 close, the midpoint (~$400) implies ~+17% upside over our 12-month horizon, before the ~$2.3B buyback and the ~2% dividend. The case rests on three things we can monitor quarter-by-quarter: a clean (43%-of-year) Q1, the early-April ACA effectuation read, and the firm-up of the 2027 MA rate in April. Each is a near-term checkpoint on the recovery; none needs to surprise to the upside for the trough thesis to hold — they only need to not deteriorate.
Thesis Scorecard Post-Earnings
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: The negative-revision cycle ends; the trough is datable | Confirmed | FY2025 on reset; 2026 quantified at ≥$25.50; Medicaid bottom −1.75% |
| Bull #2: ≥12% 2027 snap-back off a washed-out base | Confirmed (committed) | Explicit algorithm; multiple independent levers |
| Bull #3: MA margin + Stars + ASO repositioning works | Confirmed | MA to ≥2%; 9 of 11 second-blue-bid wins; Stars to ~55% 4-star+ |
| Bull #4: Carelon external engine intact | Confirmed | Ex-affiliated: Services +high-teens/low-20s, Rx +low-double-digit |
| Bear #1: Flat 2027 MA advance notice pressures the recovery | Confirmed (bear) | Real headwind to the MA leg of the 2027 bridge |
| Bear #2: Long-term segment margins structurally lowered | Confirmed (bear) | Enterprise to 5–6%; caps the re-rate magnitude |
| Bear #3: 2026 heavily front-loaded (Q1 ≈ 43%) | Neutral | Raises Q1 stakes; flu headwind pre-embedded |
Overall: Thesis strengthened and inflecting. The bull pillars (datable trough, committed recovery, working repositioning, Carelon) are now confirmed by hard numbers; the bear pillars (MA rate notice, lower long-term margins) are real but priced at ~13x a trough. The balance has tipped from "stabilizing, un-underwritable" to "bottoming, with a committed recovery and a washed-out multiple."
Action: Upgrade to Outperform from Hold. We are buying the quantified trough ahead of the re-rate, with the flat MA notice and lowered long-term margins sized into a deliberately sub-historical target multiple. The downgrade risks are specific and monitorable: a Q1 miss (high stakes given the front-loading), an adverse April ACA effectuation read, or a 2027 MA final rate that confirms rather than firms the flat advance notice. Absent those, the path of least resistance over 12 months is up.